COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19
Clinical trial NCT05092581 · TERMINATED
Trial details
- NCT number
- NCT05092581
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-16
- Primary completion
- 2022-06-09
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.